The Rise of GLP-1 and Why Taste Is Being Reconsidered

The global market for GLP-1 therapies continues to expand rapidly and is forecast to reach by $33.26 billion by 2030. As these medications become more widely used for weight management, interest is growing not only in their clinical impact but also in how they influence everyday food experiences. One area receiving increasing attention is taste perception.

Anecdotal reports from consumers suggest that flavour perception can change after starting GLP-1 therapies, ranging from reduced enjoyment of sweet foods to increased sensitivity to bitterness. This data was unearthed as part of the Horizon 10 Report by Carbery Group, exploring GLP-1 usage and was further supplemented by a social listening exercise. The results suggest that taste change is far from uncommon.

Inside the Research: A Multi-Market Consumer Study

The research covered six markets:

• United States
• United Kingdom
• Germany
• Italy
• Brazil
• Thailand

Approximately 200 active or former GLP-1 users per country were surveyed, creating a demographically representative sample.

Alongside the survey, Synergy also scraped and analysed data from dedicated GLP-1 sub-Reddits (such as r/ozempic) to explore how consumers describe taste experiences while taking GLP-1 therapies.

This combination of quantitative research and social listening provided a broader picture of how taste perception may be shifting among users.

Nearly Half of Users Report Taste Changes

Across the survey, 46% of respondents reported experiencing some form of change in taste perception since starting GLP-1 medication.

The most familiar challenges reported were:

• A general change in flavour perception
• Increased sensitivity to sweetness
• Increased sensitivity to bitterness

These responses were observed across several GLP-1 medications, including Ozempic, Wegovy and Mounjaro, suggesting the experience may be linked to the treatment mechanism rather than a specific brand.

Differences Across Age Groups and Markets

The research also revealed differences across demographics and geographies.

Younger consumers were more likely to report taste changes than older age groups, with 18–24-year-olds nearly twice as likely to report taste challenges as 55–64-year-olds. This suggests that age may influence how sensory perception shifts during GLP-1 treatment.

Geographically, the proportion of consumers reporting taste challenges varied significantly:

• United Kingdom – 65.2%
• Germany – 53.3%
• Brazil – 37.2%
• Thailand – 23.7%
• United States – 20.3%
• Italy – 15.1%

These differences highlight how cultural eating habits or dietary preferences may interact with sensory perception.

What Consumers Are Saying Online About Taste

GLP-1 and taste perception since 2022.

Across analysed discussions

• 46.3% of sentiment was neutral or mixed.
• 29.2% was positive.
• 24.5% was negative.

Among negative experiences, users most frequently mentioned:

• Metallic or chemical aftertaste
• Foods taste overly sweet.
• Reduced enjoyment of coffee.
• Chalky textures in protein products.
• Sensitivity to specific sweeteners, such as stevia

What This Could Mean for Food and Beverage Innovation

Taken together, the research suggests a potential shift in sensory expectations among some consumers using GLP-1 therapies.

Many users reported gravitating towards lighter flavour profiles, less sweetness, and simpler taste experiences, whilst struggling with indulgent or heavily sweetened products.

For food and beverage developers, these insights may become increasingly relevant as GLP-1 adoption grows. Evidence suggests that people using GLP-1 therapies often experience changes in appetite, taste perception and food preferences, including a reduced desire for sweet and fatty foods. Understanding how these preferences evolve could help guide formulation strategies across categories such as functional beverages, protein products and nutritional foods, where nutrient density and satiety are increasingly valued.

Industry analysts also suggest that GLP-1 users may prioritise products that deliver higher levels of protein, fibre and hydration in smaller portions, reflecting both reduced appetite and changing dietary priorities. In addition, the development of oral GLP-1 medications is expected to increase accessibility and potentially accelerate adoption, which may further expand the number of consumers experiencing these shifts in eating behaviour and taste perception.

Which categories are set to benefit?

Arguably, the biggest beneficiary of the GLP-1 boom has been whey protein isolates, and in particular, clear whey. Significant numbers of GLP-1 users struggle to obtain sufficient protein intake on a calorie-reduced diet, making supplementation an obvious solution.

Clear proteins have therefore become a popular choice due to their lighter taste profile (when compared to more indulgent whey protein concentrates) however, many products in this space are still reliant on high levels of sweeteners to help mask astringent off-notes, something which may be at odds with consumers saying they are actively seeking less sweet products demonstrating that there may be benefit in brands exploring masking and taste modulation solutions to make these products more palatable.

Many consumers with reduced appetites due to GLP-1 medications are even struggling to regulate their liquid consumption, meaning hydration products have also seen an uplift, with consumers turning to electrolyte supplementation throughout the day.

Finally, we also see opportunities in gut health related to GLP-1 consumers. Clinical trials for these treatments have consistently highlighted digestion challenges as the most prevalent side effects – clinical studies for Wegovy PI, for example, showed 44% of patients suffered nausea (compared to 16% in the placebo group). Diarrhoea, vomiting, constipation, and abdominal pain were also amongst the most frequently observed side effects.

As a result, consumers show a consistent interest in gut health supplements, for example, in the UK, 34% of survey respondents said they were interested in buying prebiotic supplements, whilst 28% said they were interested in probiotics.

Looking Ahead

GLP-1 therapies are already reshaping how consumers approach food, influencing appetite, portion sizes and potentially flavour perception. As adoption grows, understanding these sensory shifts may become an important part of future food and beverage innovation.

If you’d like to explore what these changes could mean for your products, get in touch with the Synergy team today.

References

Global GLP-1 Analogues Market to Reach $268.4 Billion by 2030: https://www.globenewswire.com/news-release/2026/01/30/3229410/0/en/Global-GLP-1-Analogues-Market-to-Reach-268-4-Billion-by-2030.html

Consumer Survey commissioned on behalf of Synergy by Suzy LLC and referenced as part of the Carbery Horizon 10 report: https://www.carbery.com/horizon10/

Social listening – via. Synergy’s own social listening research

GLP-1 side effects: Wegovy PI

How GLP-1 Medications Are Reshaping Food and Beverage Demand: https://www.igd.com/articles/how-glp-1-is-reshaping-health-on-the-shelf/72204

insights